Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data

被引：0
|
作者：
Ashish Sharma
M. Hafeez Faridi
Nilesh Kumar
Nikulaa Parachuri
Rohini Sharma
Baruch D. Kuppermann
Francesco Bandello
Anat Loewenstein
Carl D. Regillo
机构：
[1] Lotus Eye Hospital and Institute,Department of Vitreoretina
[2] Chicago State University,College of Pharmacy
[3] The TIPS Global Institute,Department of Healthcare
[4] University of California,Gavin Herbert Eye Institute
[5] Scientific Institute San Raffaele,Department of Ophthalmology; University Vita
[6] Tel Aviv University,Salute
[7] Mid Atlantic Retina,Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine
来源：
Eye | 2020年 / 34卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1008 / 1009
页数：1
相关论文
共 50 条
  • [41] Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
    Verma, Lalit
    Thulasidas, Mithun
    Purohit, Ajay
    Gupta, Avnindra
    Narula, Ritesh
    Talwar, Dinesh
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (02) : 347 - 351
  • [42] Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study
    Hamilton, Robin D.
    Clemens, Andreas
    Minnella, Angelo Maria
    Lai, Timothy Y. Y.
    Dai, Hong
    Sakamoto, Taiji
    Cheung, Chui Ming Gemmy
    Ngah, Nor Fariza
    Dunger-Baldauf, Cornelia
    Holz, Frank G.
    PLOS ONE, 2020, 15 (01):
  • [43] ONE YEAR REAL-WORLD OUTCOMES OF RANIBIZUMAB IN NAMD: INTERIM RESULTS FROM THE GLOBAL LUMINOUS STUDY
    Mitchell, Paul
    Gilhotra, Jagjit Singh
    Vote, Brendan
    Walsh, Meagan
    Woodcock, Chad
    Kurstjens, Nicol
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 12 - 12
  • [44] Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
    Holz, Frank G.
    Minnella, Angelo M.
    Tuli, Raman
    Yoganathan, Pradeepa
    Parikh, Soumil
    Hamilton, Robin
    PLOS ONE, 2020, 15 (12):
  • [45] Real-world outcomes of ranibizumab treatment in patients with retinal vein occlusion: the LUMINOUS™ study
    Pearce, Ian A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [46] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Chang, Yi-Sheng
    Lee, Wan-Ju
    Lim, Chen-Chee
    Wang, Shih-Hao
    Hsu, Sheng-Min
    Chen, Yi-Chian
    Cheng, Chia-Yi
    Teng, Yu-Ti
    Huang, Yi-Hsun
    Lai, Chun-Chieh
    Tseng, Sung-Huei
    SCIENTIFIC REPORTS, 2018, 8
  • [47] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Yi-Sheng Chang
    Wan-Ju Lee
    Chen-Chee Lim
    Shih-Hao Wang
    Sheng-Min Hsu
    Yi-Chian Chen
    Chia-Yi Cheng
    Yu-Ti Teng
    Yi-Hsun Huang
    Chun-Chieh Lai
    Sung-Huei Tseng
    Scientific Reports, 8
  • [48] Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study
    Puren Isik
    Selcuk Sizmaz
    Ebru Esen
    Anıl Uysal
    Nihal Demircan
    International Ophthalmology, 2023, 43 : 4171 - 4180
  • [49] Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study
    Isik, Puren
    Sizmaz, Selcuk
    Esen, Ebru
    Uysal, Anil
    Demircan, Nihal
    INTERNATIONAL OPHTHALMOLOGY, 2023, 43 (11) : 4171 - 4180
  • [50] Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan
    Kyoko Ohno-Matsui
    Makoto Suzaki
    Rie Teshima
    Nina Okami
    Eye, 2018, 32 : 1871 - 1878
12345